RxSight Analyst Price Targets - Benzinga

SPY773.42−0.49%QQQ746.56−1.47%BTC/USD81,732.42−1.85%DIA511.37+0.07%GLD378.53+0.70%TLT77.87+0.93%

RxSight Inc

RXSTNASDAQ

Trade with Public

Trade with Public

$4.83

0.0250.52%

Last update: Oct 8, 3:44 PM

$4.76

-0.04-0.83%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

RxSight Analyst Price Targets

Wall Street analyst price targets and consensus rating for RxSight (RXST).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

2Buy

5Hold

2Sell

Consensus RatingNeutral# Analysts9Avg. Consensus PT$10Upside to Avg. PT+108.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	Jefferies	Young Li	PT Cut	Hold	$7→$6
Sep 22, 2026	B of A Securities	Craig Bijou	PT Cut	Underperform	$7→$6
Aug 10, 2026	Stifel	Tom Stephan	PT Cut	Hold	$8→$7
Aug 6, 2026	UBS	Patrick Wood	PT Raise	Neutral	$6→$6
Jul 28, 2026	UBS	Patrick Wood	Assumes	Neutral	$9→$6
Jul 7, 2026	B of A Securities	Craig Bijou	PT Cut	Underperform	$8→$7
Jul 7, 2026	Needham	David Saxon	Maintained	Buy	$11
May 7, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$11→$9
May 7, 2026	Needham	David Saxon	PT Cut	Buy	$13→$11
Mar 9, 2026	Stifel	Tom Stephan	PT Cut	Hold	$10→$9
Feb 26, 2026	UBS	Danielle Antalffy	PT Raise	Neutral	$8→$9
Feb 26, 2026	Piper Sandler	Adam Maeder	PT Cut	Neutral	$11→$10
Feb 26, 2026	Needham	David Saxon	Maintained	Buy	$13
Jan 20, 2026	Piper Sandler	Adam Maeder	PT Raise	Neutral	$10→$11
Dec 2, 2025	Morgan Stanley	Patrick Wood	PT Raise	Equal-Weight	$9→$10
Nov 6, 2025	JP Morgan	Robbie Marcus	PT Raise	Underweight	$8→$9
Nov 6, 2025	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$9→$10
Nov 6, 2025	Needham	David Saxon	PT Raise	Buy	$11→$12
Aug 8, 2025	UBS	Danielle Antalffy	PT Cut	Neutral	$16→$8
Aug 8, 2025	Stifel	Tom Stephan	PT Cut	Hold	$9→$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5

B of A Securities analyst Craig Bijou maintains RxSight (NASDAQ:RXST) with a Underperform and lowers the price target from $6.5 to $5.5.

Benzinga Newsdesk

PRO
Stifel Maintains Hold on RxSight, Lowers Price Target to $7

Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $8 to $7.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3

UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.

Benzinga Newsdesk

PRO
B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $6.5

B of A Securities analyst Craig Bijou maintains RxSight (NASDAQ:RXST) with a Underperform and lowers the price target from $8 to $6.5.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on RxSight, Maintains $11 Price Target

Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $11 price target.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $9

Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $11 to $9.

Benzinga Newsdesk